Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer

NCT04088032 is registered in ClinicalTrials.gov with Alison Stopeck as lead sponsor.

NCT NCT04088032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04088032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Neoadjuvant Clinical Trial of Combination Therapy With Abemaciclib, Durvalumab (MEDI4736), and an Aromatase Inhibitor in Locally Advanced Hormone Receptor Positive Breast Cancer
Lead sponsor
Alison Stopeck
Phase
Phase 1
Overall status
Withdrawn
Start date
October 1, 2019
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, hormone receptor positive malignant neoplasm of breast, locally advanced breast cancer